Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
$13.16
-1.4%
$10.90
$7.21
▼
$20.46
$2.92B0.654.13 million shs1.57 million shs
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
$6.75
0.0%
$11.40
$6.53
▼
$24.27
$390.17M0.751.34 million shs758,060 shs
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
$18.35
-6.0%
$21.18
$17.90
▼
$42.21
$2.20B0.151.21 million shs1.42 million shs
Precigen, Inc. stock logo
PGEN
Precigen
$4.22
+1.3%
$6.53
$3.04
▼
$8.98
$1.51B1.014.96 million shs3.55 million shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
-1.62%+0.76%+18.79%+35.57%-16.36%
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
+0.75%-12.34%-45.39%-65.96%-61.63%
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
-1.17%-2.30%-9.26%-30.00%-49.48%
Precigen, Inc. stock logo
PGEN
Precigen
-2.58%-10.73%-39.09%-42.22%-1.42%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
$13.16
-1.4%
$10.90
$7.21
▼
$20.46
$2.92B0.654.13 million shs1.57 million shs
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
$6.75
0.0%
$11.40
$6.53
▼
$24.27
$390.17M0.751.34 million shs758,060 shs
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
$18.35
-6.0%
$21.18
$17.90
▼
$42.21
$2.20B0.151.21 million shs1.42 million shs
Precigen, Inc. stock logo
PGEN
Precigen
$4.22
+1.3%
$6.53
$3.04
▼
$8.98
$1.51B1.014.96 million shs3.55 million shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
-1.62%+0.76%+18.79%+35.57%-16.36%
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
+0.75%-12.34%-45.39%-65.96%-61.63%
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
-1.17%-2.30%-9.26%-30.00%-49.48%
Precigen, Inc. stock logo
PGEN
Precigen
-2.58%-10.73%-39.09%-42.22%-1.42%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
2.50
Moderate Buy$17.5033.03% Upside
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
2.71
Moderate Buy$36.82445.62% Upside
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
2.83
Moderate Buy$49.82171.53% Upside
Precigen, Inc. stock logo
PGEN
Precigen
2.50
Moderate Buy$13.25214.35% Upside

Current Analyst Ratings Breakdown

Latest AVTX, ADMA, NAMS, and PGEN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/16/2026
Precigen, Inc. stock logo
PGEN
Precigen
Reiterated RatingBuy$12.00 ➝ $11.00
11/11/2026
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
Boost Price TargetOverweight$52.00 ➝ $61.00
11/6/2026
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
Lower Price TargetOutperform$22.00 ➝ $20.00
11/5/2026
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
Set Price Target$18.00
11/5/2026
Precigen, Inc. stock logo
PGEN
Precigen
Set Price Target$12.00
11/5/2026
Precigen, Inc. stock logo
PGEN
Precigen
Reiterated RatingMarket Outperform
11/5/2026
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
Boost Price TargetNeutral$12.00 ➝ $13.00
11/5/2026
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
Lower Price TargetBuy$48.00 ➝ $46.00
11/5/2026
Precigen, Inc. stock logo
PGEN
Precigen
Boost Price TargetMarket Outperform$11.00 ➝ $12.00
11/4/2026
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
Reiterated RatingSell (D-)
10/26/2026
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
Set Price Target$16.00
(Data available from 11/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
$519.15M5.62$0.63 per share20.73$1.98 per share6.64
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
$60K6,502.82N/AN/A$7.55 per share0.89
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
$22.50M97.79N/AN/A$5.26 per share3.49
Precigen, Inc. stock logo
PGEN
Precigen
$9.68M156.12N/AN/A$0.23 per share18.33
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
$146.93M$0.7717.0815.30N/A35.14%42.56%26.96%N/A
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
-$78.26M-$2.52N/AN/AN/AN/A-34.21%-29.84%N/A
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
-$203.82M-$1.69N/AN/AN/A-789.95%-31.39%-28.32%N/A
Precigen, Inc. stock logo
PGEN
Precigen
-$250.64M$0.1042.156.69N/A15.55%57.93%14.43%N/A

Latest AVTX, ADMA, NAMS, and PGEN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/5/2026Q3 2026
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
-$0.5883-$0.34+$0.2483-$0.34N/AN/A
11/4/2026Q3 2026
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
$0.1967$0.23+$0.0333$0.22$138.11 million$141.10 million
11/4/2026Q3 2026
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
-$0.4718-$0.14+$0.3318-$0.14$8.82 million$19.16 million
11/4/2026Q3 2026
Precigen, Inc. stock logo
PGEN
Precigen
$0.06$0.08+$0.02$0.08$71.55 million$74.15 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
N/AN/AN/AN/AN/A
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
N/AN/AN/AN/AN/A
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
N/AN/AN/AN/AN/A
Precigen, Inc. stock logo
PGEN
Precigen
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
0.45
6.04
3.25
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
N/A
16.63
16.63
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
N/A
11.76
11.76
Precigen, Inc. stock logo
PGEN
Precigen
1.12
5.58
4.83

Institutional Ownership

CompanyInstitutional Ownership
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
75.68%
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
87.06%
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
89.89%
Precigen, Inc. stock logo
PGEN
Precigen
33.51%

Insider Ownership

CompanyInsider Ownership
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
3.90%
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
4.46%
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
12.74%
Precigen, Inc. stock logo
PGEN
Precigen
41.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
647221.85 million213.20 millionOptionable
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
3357.82 million55.24 millionOptionable
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
100119.93 million104.65 millionOptionable
Precigen, Inc. stock logo
PGEN
Precigen
47358.55 million210.11 millionOptionable

Recent News About These Companies

Precigen (NASDAQ:PGEN) Stock Rating Reaffirmed as Buy by B. Riley Financial
Precigen, Inc. (PGEN) - What Are Brokerages Saying About This Stock?
Precigen Earnings Call Highlights PAPZIMEOS Growth
What Makes Precigen (PGEN) a New Buy Stock
FY2026 EPS Estimates for Precigen Increased by HC Wainwright
Precigen (PGEN) Stock Looks Fully Priced On Current Earnings
Precigen (PGEN) Q3 2026 Earnings Call Transcript
Precigen, Inc. (PGEN) Q3 2026 Earnings Call Transcript

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADMA Biologics stock logo

ADMA Biologics NASDAQ:ADMA

$13.16 -0.19 (-1.39%)
Closing price 03:59 PM Eastern
Extended Trading
$13.27 +0.12 (+0.90%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Avalo Therapeutics stock logo

Avalo Therapeutics NASDAQ:AVTX

$6.75 0.00 (-0.03%)
Closing price 03:58 PM Eastern
Extended Trading
$6.76 +0.01 (+0.18%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

NewAmsterdam Pharma stock logo

NewAmsterdam Pharma NASDAQ:NAMS

$18.35 -1.16 (-5.96%)
Closing price 03:58 PM Eastern
Extended Trading
$18.39 +0.04 (+0.23%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Precigen stock logo

Precigen NASDAQ:PGEN

$4.22 +0.06 (+1.32%)
Closing price 03:59 PM Eastern
Extended Trading
$4.20 -0.01 (-0.24%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.